Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
85 shs
Market Capitalization
$5.40 billion
P/E Ratio
Dividend Yield
Price Target
HKMPF stock logo

About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

HKMPF Stock Price History

HKMPF Stock News Headlines

Hikma Pharmaceuticals PLC (HKMPF)
Hikma Pharma FY Profit Increases
Stocks Open Lower, Weighed Down by Rising Bond Yields
Hikma Pharmaceuticals Appoints Riad Mishlawi CEO
Hikma Pharma names Mishlawi as next CEO
See More Headlines
Receive HKMPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/3 Dividend
Dividend Payable
Fiscal Year End

Industry, Sector and Symbol

Private households
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$2.88 billion
Cash Flow
$3.33 per share
Book Value
$10.03 per share


Free Float
Market Cap
$5.40 billion
Not Optionable
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 67)
    Executive Chairman
    Comp: $2.8M
  • Mr. Riad Ali Mishlawi (Age 60)
    CEO & Director
    Comp: $1.1M
  • Mr. Mazen Samih Taleb Darwazah (Age 66)
    Executive Vice Chairman & President of MENA
    Comp: $2.3M
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 52)
    Chief Financial Officer
  • Patricia Bousfield
    Chief Information Officer
  • Mr. Guy Featherstone
    Associate Director of Investor Relations
  • Mr. Samuel Park
    General Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 59)
    CPA, Executive Vice President of Corporate Development and M&A
  • Mr. Hussein Omar Arkhagha
    Chief People Officer
  • Ms. Susan Ringdal
    Executive Vice President of Strategic Planning & Global Affairs

HKMPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HKMPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HKMPF, but not buy additional shares or sell existing shares.
View HKMPF analyst ratings
or view top-rated stocks.

How have HKMPF shares performed in 2024?

Hikma Pharmaceuticals' stock was trading at $22.7850 on January 1st, 2024. Since then, HKMPF shares have increased by 7.5% and is now trading at $24.50.
View the best growth stocks for 2024 here

Are investors shorting Hikma Pharmaceuticals?

Hikma Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,849,700 shares, an increase of 6.2% from the April 15th total of 1,741,900 shares. Based on an average trading volume of 200 shares, the short-interest ratio is presently 9,248.5 days.
View Hikma Pharmaceuticals' Short Interest

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Wednesday, March 6th. Investors of record on Friday, March 22nd will be given a dividend of $0.47 per share on Friday, May 3rd. The ex-dividend date of this dividend is Wednesday, March 20th. This is an increase from the stock's previous dividend of $0.25.
Read our dividend analysis for HKMPF

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (OTCMKTS:HKMPF) pays an annual dividend of $0.94 per share and currently has a dividend yield of 3.84%.
Read our dividend analysis for HKMPF.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HKMPF) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners